Rahnama Inchehsablagh Behnaz, Ghadiri Soufi Farhad, Koochakkhani Shabnaz, Azarkish Fariba, Farshidi Hossein, Eslami Mahdiye, Mahmoodi Masoumeh, Soltani Nepton, Eftekhar Ebrahim
Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Indian J Clin Biochem. 2023 Jan;38(1):59-66. doi: 10.1007/s12291-022-01032-0. Epub 2022 Apr 9.
Magnesium seems to play a role in improving cardiovascular function, but its exact mechanism is unknown. In this study, we hypothesized that magnesium could modulate the expression of genes involved in atherosclerosis. The aim of the present investigation was to evaluate the effect of magnesium sulfate on the expression of sirtuin1 (SIRT1), tumor protein p53 (TP53), and endothelial nitric oxide synthase (eNOS) genes in patients with atherosclerosis. This study was a placebo-controlled double-blind randomized clinical trial on 56 patients with angiographically proven atherosclerosis. Participants were randomly divided into two groups receiving 300 mg/day magnesium sulfate (n = 29) and placebo (n = 27) for three months (following up every month). Fasting blood samples were taken before and after the intervention and total RNA was extracted and used to evaluate the expression level of SIRT1, TP53, and eNOS genes by Real-Time PCR. The expression of eNOS gene was significantly increased ( < 0.0001) and the expression of TP53 gene was decreased ( = 0.02) in the magnesium sulfate group compared to the placebo group. But SIRT1 gene expression was not significantly different between the two groups. Our findings demonstrate that magnesium sulfate supplementation may have a protective role against the progression of atherosclerosis through upregulation of eNOS and downregulation of TP53 gene. : This present clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT) with the registration code of "IRCT20151028024756N3", https://www.irct.ir/trial/29097?revision=114102. Registered on 16 December 2019.
镁似乎在改善心血管功能方面发挥作用，但其确切机制尚不清楚。在本研究中，我们假设镁可以调节参与动脉粥样硬化的基因表达。本研究的目的是评估硫酸镁对动脉粥样硬化患者中沉默调节蛋白1（SIRT1）、肿瘤蛋白p53（TP53）和内皮型一氧化氮合酶（eNOS）基因表达的影响。本研究是一项安慰剂对照的双盲随机临床试验，对56例经血管造影证实患有动脉粥样硬化的患者进行。参与者被随机分为两组，连续三个月每天分别服用300毫克硫酸镁（n = 29）和安慰剂（n = 27）（每月随访）。在干预前后采集空腹血样，提取总RNA，并通过实时聚合酶链反应用于评估SIRT1、TP53和eNOS基因的表达水平。与安慰剂组相比，硫酸镁组中eNOS基因的表达显著增加（<0.0001），TP53基因的表达降低（=0.02）。但两组之间SIRT1基因表达无显著差异。我们的研究结果表明，补充硫酸镁可能通过上调eNOS和下调TP53基因对动脉粥样硬化的进展起到保护作用。：本临床试验已在伊朗临床试验注册中心（IRCT）注册，注册号为“IRCT20151028024756N3”，https://www.irct.ir/trial/29097?revision=114102。于2019年12月16日注册。
